CTRI/2021/04/032664已完成3 期
A multicentre prospective randomized double-blind placebo-controlled study to evaluate the efficacy and safety of ketorolac 30 mg sublingual tablet in the acute treatment of migraine headache - NA
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and female adult patients aged 18 to 65 years and having the diagnosis of migraine with or without aura according to the International Headache Societys criteria for migraine ICHD3 2018
- •History of diagnosis of migraine before the age of 50 years
- •Subjects must be compliant with self administration of medication and willing to fillup the migraine diary provided to them as required for the study
- •At least a 1year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders 3rd edition beta version ICHD3
- •Migraine episodes that are separated by at least 72 hours of headache pain freedom will be included
- •History of 2 to 8 migraine attacks per month with moderate to severe headache pain in each of the 3 months prior to Screening
排除标准
- •All headache types other than migraine
- •Has taken medication for acute treatment of headache including acetaminophen nonsteroidal anti inflammatory drugs NSAIDs triptans ergotamine opioids or combination analgesics on 10 or more days per month in the previous 3 months
- •Required hospital treatment of a migraine attack 3 or more times in the previous 6 months
- •Has a chronic non headache pain condition requiring daily pain medication
- •Has a history of malignancy in the prior 5 years except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- •Has a history of any prior gastrointestinal conditions eg diarrhea syndromes inflammatory bowel disease that may affect the absorption or metabolism of the investigational product participants with prior gastric bariatric interventions which have been reversed are not excluded
- •Patients with active peptic ulcer disease recent gastrointestinal bleeding or perforation
- •Patients with a history of peptic ulcer disease or gastrointestinal bleeding
- •Elderly patients at a greater risk for serious gastrointestinal events age more than 65 years
- •Has a history of hepatitis within the previous 6 months
- •Pregnancy or breastfeeding
- •Subjects who within one year had a clinically significant medical history of bleeding problems coagulation abnormalities hemorrhagic disease anemia bone marrow suppression immunosuppression motility dysfunction or any condition that could interfere with the absorption distribution metabolism or excretion of the study medication
- •Subjects who are diagnosed and or treated for inflammatory bowel disease or pancreatic disease serious cardiovascular disease or history of serious cardiovascular disease or stroke renal hepatic endocrine pulmonary neurologic disease Type I or II diabetes mellitus uncontrolled hypertension or malignancy not in remission
- •Subjects who are taking drugs like antiplatelet agents and or anticoagulants
- •Uncontrolled hypertension Systolic greater than 150 and Diastolic greater than 95 mm of Hg
研究者
相似试验
进行中（未招募）
不适用
Randomised, double-blind, prospective multi-centre study to compare the analgesic efficacy and safety of a paracetamol/codeine/caffeine fixed-dose combination (Azur® compositum) with paracetamol/codeine (Azur® compositum SC) in patients with moderate pain after third molar dental surgery - Azurcomp-MolarPost-operative pain after a dental surgical procedure (third molar surgery).MedDRA version: 9.1Level: LLTClassification code 10054711Term: Postoperative painEUCTR2007-002784-27-DESteiner & Co. Deutsche Arzneimittelgesellschaft mbH & Co. KG
进行中（未招募）
1 期
The Iron and Muscle StudyEUCTR2018-000144-25-GBKing's College Hospital NHS Foundation Trust70
已完成
4 期
A clinical trial to study the effect of, Fluticasone Nasal Spray BP (Mfd. By Biodeal Laboratories Pvt. Ltd.) Vs Fluticasone Nasal Spray BP (Mfd. By Glaxosmithkline Pharmaceuticals Ltd) in patients with Allergic RhinitisCTRI/2010/091/000135Biodeal Laboratories Pvt. Ltd508, G.I.D.C Estate, Wadhwan City, Dist Surendranagar,Gujarat - 363035125
进行中（未招募）
1 期
Prospective multicenter randomized double-blind study comparing caspofungin to placebo for the treatment of ICU yeast intra-abdominal infectiointraabdominal yeast infectionEUCTR2018-000407-16-FRCHU Amiens-Picardie448
进行中（未招募）
1 期
Prospective multicenter randomized double-blind study comparing caspofungin to placebo for the treatment of ICU yeast intra-abdominal infectioyeast intra-abdominal infection, peritonitisCTIS2024-516266-11-00Centre Hospitalier Universitaire Amiens Picardie448